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Abstract To study enzymatic activity and activation conditions 
of the recently identified novel protein kinase C ~t (PKC~t) 
subtype, epitope tagged PKC~t was propagated in the baculovirus 
expression system and was purified to homogeneity. PKC~t 
displays high affinity phorbol ester binding (Kd = 7 nM) 
resulting in enhanced phosphatidylserine-dependent kinase activ- 
ity. From various lipid second messengers known to activate 
PKCs only diacylglycerol and Ptdlns-4,5-P2, were found to 
promote PKCp~ kinase activity. Two peptides derived from the 
glycogen synthase, GS-peptide and syntide 2, were found to be 
phosphorylated efficiently in vitro. MARCKS (myristoylated 
alanine-rich C-kinase substrate) served as an in vitro substrate 
for PKC~t too. However, in contrast to other PKCs, a peptide 
derived from the MARCKS phosphorylation domain is phos- 
phorylated only at serine 156, and not at serines 152 and 163, 
implicating a differential regulation by PKC~t. 
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1. Introduction 
We previously reported the cloning and characterization f 
a novel PKC subtype named PKCg [6]. The lack of a typical 
pseudosubstrate site as well as the presence of two unique 
amino-terminal hydrophobic domains together with the unu- 
sually large size of the molecule are characteristic features of 
this PKC isozyme. Furthermore, the presence of a pleckstrin 
homology (PH) domain [7] in the regulatory region of PKCla 
is so far unique within the PKC family. Moreover, expression 
and functional analysis of the homologous mouse gene, 
termed PKD [8], showed an atypical substrate specificity in 
vitro [9]. Taken together, these findings suggest hat PKCg/ 
PKD might constitute a further PKC subgroup with cellular 
functions distinct from the already known PKC subtypes. 
Recombinant PKCs, produced in the baculovirus ystem 
have been shown to be valuable tools for the characterization 
of enzymatic properties like activation conditions, in vitro 
substrate phosphorylation a d in defining selective kinase in- 
hibitors [10,11]. We here describe the expression, purification 
and biochemical characterization f PKCg expressed in insect 
cells. 
Protein kinases C (PKC) define a family of serine/threonine 
specific kinases considered as important regulatory enzymes in 
multiple cellular esponses. They are activated by lipid second 
messengers, predominantly diacylglycerol [1], in response to 
various extracellular agonists like hormones, neurotransmit- 
ters, growth factors and cytokines (for reviews see [24]). So 
far, 11 PKC isoforms have been characterized at the molecu- 
lar level. Based on the primary structure and in vitro activa- 
tion requirements, he PKC family can be grouped into three 
major classes: Ca2+-dependent, conventional PKCs; Ca2+-in - 
dependent novel PKCs and atypical PKCs. At present, the 
understanding of the physiological role of the various PKC 
members i still limited. However, despite the fact that in vivo 
substrates are largely unknown, tissue specific expression and 
differential intracellular location suggest distinct functions of 
individual PKC isotypes in signal transduction and cellular 
metabolism [5]. 
*Correspondending author. Fax: (49) (711) 685-7484. 
Abbreviations: PKC, protein kinase C; PDBu, phorbol 12,13-dibuty- 
rate; Ptdlns-4,5-P2, L-~-phosphatidyl-D-myo-inositol-4,5-bisphos- 
phate; PMSF, phenylmethylsulfonylfluoride; PS, L-a-phosphatidyl-L- 
serine; DAG, 1,2-dioctanoyl-sn-glycerol; MARCKS, myristoylated 
alanine-rich C-kinase substrate; L-PC, L-C~-lysophosphatidylcholine; 
PA, L-c~-dipalmitoyl phosphatidic acid; AA, arachidonic acid; Cer, 
Cl~*ceramide; HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfo- 
nic acid. 
2. Materials and methods 
2.1. Construction and cloning of PKCI.t c-myc tagged recombinant 
baculoviruses 
Two oligonucleotides r presenting the complementary strands of 
the c-myc epitope were cloned into the SmaI restriction site of the 
pCDM8 [12] vector containing the human PKC~t cDNA devoid of the 
3'-untranslated region. This results in c-myc tagging of PKCp. car- 
boxy-terminal of the predicted protease cleaveage site of the leader 
peptide and amino-terminal of the putative transmembrane domain 
[6]. The c-myc PKCIa cDNA was isolated as a 3.2 kb XholINsiI frag- 
ment and, after filling up 5'-overhanging ends with T4 DNA poly- 
merase, ligated into the baculotransfer vector pVL 1392 linearized 
with Sinai. pVL1392/PKC~t was transfected into Sf158 cells using 
linearized and modified BACULO GOLD Baculovirus DNA (Phar- 
mingen) according to the manufacturers instructions and standard 
procedures [13]. Equivalents of40,000 cells were analysed by Western 
blot analysis with a monoclonal anti c-myc antibody (Cambridge 
Research Biochemicals), diluted 1:1000 in PBS using an alkaline 
phosphatase based etection system. 
2.2. Purification of baculovirus produced PKCI.t by affinity 
chromatography 
10 s infected insect cells were lysed in 10 ml extraction buffer (20 
mM Tris-HC1 pH 7.5, 5 mM EDTA, 5 mM EGTA, 500 nM PMSF, 
100 lag/ml leupeptin, 20 lag/ml trypsininhibitor, 200 ~tg/ml iodineace- 
tamide) by sonification (20 × 1 s). Cell debris was removed by centrif- 
ugation for 10 min at 100,000 ×g and the supernatant passed through 
a 0.2 lain sterile filter. For affinity chromatography, a PKCla antibody 
column (3 mg monoclonal PKC~t JP1 antibody [14] coupled to 2 ml 
activated sepharose according to standard protocols) was equilibrated 
with buffer A (20 mM Tris-HC1 pH 7.5, 5 mM EDTA, 5 mM EGTA) 
at a flow rate of 1 ml/min, followed by the application of the cell 
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extract at a flow rate of 0.3 ml/min. The column was washed with 10 
column volumes buffer A at a flow rate of 1 ml/min and elution was 
performed either with 5-10 column volumes buffer B (buffer A; pH 
10.5), collected in 1 ml fractions containing 1/15 volume of 1 M 
HEPES pH 6.8 to neutralize the samples or with 5-10 column vol- 
umes buffer C (3 M MgC12, 20 mM Tris-HCl pH 7.5). The fractions 
were tested for their content of PKCla by SDS-PAGE followed by 
silver staining. MgCI2 was removed by gel filtration or dialysis against 
20 mM Tris-HCl, pH 7.5. A typical preparation yielded approxi- 
mately 100-200 lag of PKCla. After adding 10% glycerol, purified 
PKCla was stored in aliquots at -20°C. PKCgl was isolated as de- 
scribed [15]. 
2.3. [3H]PDBu binding 
100 ng of purified PKCla (= 10/.tl) or supernatant, containing 25 lag 
total protein and an equivalent amount of PKCla protein (as esti- 
mated by Western blot analysis), were used for the binding assay by 
incubating 1 h at 4°C in a total volume of 100 lal. The mixture con- 
tained 20 mM Tris-HCl, pH 7.5, 12 mM MgCI2, 5 mM EGTA, 1 rag/ 
ml BSA, 100 lag/ml phosphatidylserine and the indicated amounts of 
[3H]PDBu (15.1 Ci/mMol, Amersham). Free [3H]PDBu was removed 
by rapid filtration through glass fiber filters, followed 10 times wash- 
ing with 20 mM Tris-HC1, pH 7.4, 10 mM MgSO4, 1 mM CaCI.~ and 
counting by digital autoradiography (Berthold Digital Autoradio- 
graph). Specific binding represents the difference between total bind- 
ing and non-specific binding, measured in the presence of unlabelled 
100 laM PDBu. Scatchard analysis was calculated using a modified 
Excel (Microsoft) program. 
2.4. Substrate and autophosphorylation of PKCla 
Substrate phosphorylation f PKCla was measured in a modified 
Triton X-100 mixed micellar assay as described [16] using affinity 
purified enzyme. Peptides were used at a concentration of 60 ~tM, 
histone IllS, myelin basic protein and myosine at concentrations of 
200 lag/ml. Extracts (5 lag total protein per assay) of PKCla transfected 
Sf158 cells were used to estimate cofactor dependence of kinase activ- 
ity. The concentrations of cofactors used are indicated in the figure 
legend. Assays were carried out as described for the purified enzyme. 
L-C~-lysophosphatidylcholine and L-c~-dipalmitoyl phosphatidic acid 
were purchased from Sigma. Semisynthetic C16-ceramide was pur- 
chased from Biomol. L-a-phosphatidyl-D-myo-inositol-4,5-bisphos- 
phate (Ptdlns-4,5-P2) was purchased from Boehringer Mannheim. Au- 
tophosphorylation f PKCp was carried out using 50 ng of the 
purified enzyme, fractionated by SDS-PAGE and visualized by auto- 
radiography. Two-dimensional phosphopeptide mapping was carried 
out as described [16]. 
3. Results 
3.1. Expression and purification of c-myc epitope tagged PKC~t 
in Sf158 cells 
An amino-terminal epitope tagged derivate of the PKC~t 
cDNA was constructed to facilitate detection of the cDNA 
gene product independent of endogeneous PKC~t by epitope- 
tag specific antibodies. The epitope EQKLISEEDL derived 
from the human c-myc gene, is recognized by the monoclonal 
antibody 9El0 [17]. Functional expression of intact c-myc 
tagged PKCp. was analysed by kinase assays in immunopre- 
cipitates of PKCla, obtained with the 9El0 c-myc antibody, 
after transient expression in COS cells. As shown in Fig. 1 
(lane 1 versus lane 2) a specific protein band of approximately 
120 kDa representing the autophosphorylated PKC~t, was de- 
tectable in PKC~t transfectants but not in vector control trans- 
fectants. The obtained c-myc tagged PKCp. showed a slightly 
reduced electrophoretic mobility upon SDS-PAGE, corre- 
sponding to an approximate 5 kDa increase in molecular 
mass, compared to endogeneous PKCIa from HepG2 cells 
(data not shown). 
To express epitope tagged PKC~t in Sf158 cells, a PKC~t 
cDNA fragment was cloned into the baculotransfer vector 
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Fig. 1. Expression and purification of c-myc epitope tagged PKCla. 
lanes 1 and 2: Autophosphorylation assay of immunoprecipitates 
with the anti c-myc 9El0 antibody from COS cells transiently ex- 
pressing PKC/a (lane 1). Lane 2, vector control. Lanes 3 and 4: 
Western Blot detection with the 9El0 antibody of PKCp present in 
baculovirus infected (lane 3) and uninfected (lane 4) Sf158 cells. 
Lane 5: Silver staining of extracts from Sf158 cells infected with re- 
combinant PKCla-baculovirus. Lane 6: Silver staining of affinity 
purified PKCla. Lane 7: Autophosphorylation f affinity purified 
PKCla. Autoradiographs from lane 1, 2 and 7 were exposed over- 
night. 
pVL 1392, transfected into Sf158 cells and analysed for 
PKC~t expression. From lysates equivalent o 40,000 cells, 
specific signals were detectable by Western blot analysis with 
the monoclonal 9El0 anti c-myc antibody (Fig. 1, lane 3), the 
PKCIa specific antibody JP1 [14] as well as with a PKCIa 
rabbit antiserum (data not shown). No immunoreactive ma- 
terial could be detected in non-transfected Sf158 cells (Fig. 1, 
lane 4). 
For further biochemical studies it was desirable to obtain 
highly purified PKC~t protein. Therefore, a purification pro- 
tocol based on affinity chromatography with the PKC~t spe- 
cific antibody JPI was established. This approach yielded 
highly purified PKC~t in a fast, single step purification proce- 
dure. The purity of the preparation was assessed by silver 
staining indicating that PKC~t could be eluted to greater 
than 90% purity (Fig. 1, lane 6 versus lane 5). Purified 
PKC~t retained its kinase activity as shown by in vitro auto- 
phosphorylation (Fig. I, lane 7) and was used for further 
biochemical analyses. 
3.2. Purified PKCp binds phorbol ester 
The aminoterminal region of PKqt  contains two conserved 
cysteine-clusters with the characteristic HX12CX2CXn- 
CX2CX4HX2CXTC consensus equence, typical for all mem- 
bers of the PKC family. These domains represent the struc- 
tural motivs responsible for high affinity phorbol ester binding 
[10]. In distinction to all other PKC subtypes with two cy- 
steine domains which are separated by 15-20 amino acids, 
PKC~t shows a unique spacing of 80 amino acids of its cy- 
steine domains. In our initial studies, only a weak binding of 
phorbol esters in cellular extracts of HeLa and COS PKC~t 
transfectants could be detected, questioning a direct role of 
phorbol ester in PKC~t activation [6]. However, as a signifi- 
cant phosphatidylserine/phorbol ester dependent stimulation 
of PKCIa autophosphorylation could be subsequently demon- 
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Fig. 2. Phorbol ester binding of PKC~t. Left panels show dose response curves, right panels Scatchard plots of [3H]PDBu binding of purified 
PKCkt enzyme (upper panel) or cellular extracts (lower panel). All measurements were carried out in duplicates. One of three identical experi- 
ments is shown. 
strated in specific PKCla immunoprecipitates [14], we wished 
to scrutinize the phorbol ester binding capacity of PKC~t. 
Extracts from Sf158 cells expressing PKCkt already showed 
an approximately 7 fold enhancement in [3H]PDBu binding 
compared to control cells which could be enhanced by adding 
phosphatidylserine micelles approximately 40 fold (data not 
shown). Binding of [3H]PDBu to PKCp, expressed in Sf158 
cells followed saturable kinetics which is shown in Fig. 2 
(left panels). Scatchard plot analysis of [3H]PDBu binding 
of purified PKCIa suggests the presence of a single class of 
high affinity binding sites with a dissociation constant (Ka) of 
7 nM (Fig. 2, right upper panel). Scatchard analysis of 
[3H]PDBu of cellular extracts from Sf158 expressing PKCa 
were carried out in parallel as a control. The calculated is- 
sociation constant of 12 nM for PKCa (data not shown) is in 
accordance with previously published ata [18,19]. Scatchard 
analysis of PKCkt expressing Sf158 extracts (Fig. 2b, right 
lower panel) revealed a Kd of 10 nM, which only slightly 
differed from the value of the Ka determined for the purified 
enzyme. Accordingly, the data presented here provide unequi- 
vocal evidence that recombinant, baculovirus produced PKCI.t 
serves, in vitro, as a high affinity phorbol ester receptor with 
binding characteristics identical to classical PKCs, such as 
PKCtx. 
3.3. Substrate specificity of PKCI.t and characerization of 
phosphorylation sites 
As a first step towards defining specific functions of PKC~t, 
we examined potential in vitro substrates. PKCkt phosphory- 
lation of several representative proteins and specific peptides 
known to be phosphorylated by various PKCs was analysed. 
The synthetic peptide GS (PLSRTLSVAALL), which was de- 
monstrated to be a PKC substrate of activated T-cells [20], 
was found to be the most efficiently phosphorylated substrate 
of PKCIs (Table 1). Phosphoamino acid analysis showed ex- 
clusive phosphorylation serine residues. Furthermore phos- 
phopeptide mapping revealed phosphorylation on the serine 
at position 7 of the GS-peptide (data not shown) as demon- 
strated earlier for other PKCs subtypes [21]. Syntide 2 
(PLARTLSVAGLPGKK), a synthetic peptide derived from 
the glycogen synthase [22], which has been previously reported 
to be specifically phosphorylated by PKD [8] the mouse 
homologue of PKCp., was also efficiently phosphorylated by 
PKCkt (Table 1). 
A major and specific PKC substrate is the ubiquitiously ex- 
pressed MARCKS protein [23,24]. A murine MARCKS de- 
rived peptide containing five potential serine phosphorylation 
sites (KKKKKRFS152FKKS156FKLS160GFS163FKKS167K) 
can be efficiently phosphorylated by cPKCs, nPKCs aPKCs 
[16] and by PKC~t as shown here (Table 1). As revealed by 
Table 1 
Substrate phosphorylation f PKC~t 
Substrate Relative PKCp. activity 
(cpm/assay) + S.D. 
No substrate added/ 893 +491 
autophosphorylation 
Synthide 2 63403 + 10403 
MARCKS peptide 15089 + 741 
Kemptide 1232 + 433 
EGF-receptor peptide 2473 + 526 
GS-peptide 84960 + 7181 
Histone IllS 4132 + 563 
Myelin basic protein (MBP) 11313 + 401 
Myosin 1305 _+ 478 
Purified PKCp. was used to phosphorylate r presentative PKC sub- 
strates as described in the method section. Peptides were used at a 
concentration of 60 laM, protein substrates were used at 200 p.g/ml. 
Measurements were carried out in triplicates, data shown represent 
mean values + S.D. 
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Fig. 3. Two dimensional phosphopeptide mapping of MARCKS. The MARCKS-peptide (25 lag/ml) was phosphorylated by purified PKCla or 
by PKCI31 in the presence of 125 lxg/ml phosphatidylserine and 1.25 Bg/ml phorbol-12,13-dibutyrate t 30°C for 2 h, resolved by SDS-PAGE 
and transferred to a nitrocellulose membrane. The peptide was digested on the membrane by trypsin at 37°C overnight. The tryptic phospho- 
peptides were resolved in the first dimension by thin-layer electrophoresis at pH 3.5 and by thin-layer chromatography in the second imension. 
The peptide mapping after PKC/.t phosphorylation shows two distinct spots representing the peptides SI~6FK and KS156FK due to alternative 
tryptic leavage. The peptide map obtained by PKCfl is identical as described [15]. Exposure time was overnight. 
peptide sequence analysis only three out of five potential 
phosphorylation sites corresponding to serine residues 152, 
156 and 163 have been previously identified to be phosphory- 
lated by several PKCs [16]. Phosphopeptide analyses of the 
MARCKS peptide upon maximum phosphorylation by 
PKC~t showed two distinct spots (Fig. 3, left panel) in con- 
trast to five spots obtained by MARCKS phosphorylation 
with PKCS1 (Fig. 3, right panel). Both spots correspond to 
partial digested, serine 156 phosphorylated tryptic peptides as 
revealed by amino acid sequence analysis of each spot [16]. 
These results demonstrate that PKC~t, in contrast o other 
PKC subtypes can phosphorylate only one of five potential 
PKC specific phosphorylation sites of the MARCKS peptide. 
In contrast o the already described peptide substrates only 
a weak phosphorylation f Kemptide (LRRASLG) and of an 
EGF receptor derived peptide (LRTLRR) by PKC~t could be 
detected. Moreover, Histone IIIS was also found to be only a 
minor substrate of PKC~t, whereas myelin basic protein was 
phosphorylated significantly better which is in accordance to 
previous observations [14]. As the kinase domain of PKC~t 
exerts significant homologies to the myosin light chain kinase 
(MLCK) [6], myosin phosphorylation was analysed. However, 
no significant phosphorylation could be detected (Table 1), 
making it rather unlikely that myosin will be an in vivo sub- 
strate of PKQt. 
3.4. Requirement of lipids as activation factors for PKC~t 
To analyse the role of lipid messengers in in vitro activation 
of recombinant PKC~t, several known mediators of PKC ac- 
tivation were tested for stimulation of PKC~t kinase activity 
by analysis of in vitro phosphorylation of the syntide 2 pep- 
tide (Table 2). Like endogeneous PKC~t [6], PKQt  expressed 
in insect cells showed a constitutive kinase activity, which 
could be enhanced approximately twofold by adding phos- 
phatidylserine micelles to the in vitro kinase assay (Table 2). 
Addition of diacylglycerol and PDBu each strongly enhanced 
substrate phosphorylation, with an approximately 5 and 3 
fold increase, respectively, compared to the level obtained 
with phosphatidylserine (PS) alone. Interestingly, phosphati- 
dylinositol-4,5-phosphate (P dlns-4,5-P2), previously shown to 
be a weak activator of nPKCs and of cPKCs [25-27] also 
enhanced syntide 2 peptide phosphorylation by PKC~t ap- 
proximately twofold. In contrast, ceramide, recently shown 
to be an activator of aPKC~ in vitro and in vivo [28] did 
not stimulate PKC~t kinase activity. As cPKC isozymes can 
be activated in vitro by the phospholipase A2 derived second 
messengers like lysophosphatidylcholine (L-PC) and arachido- 
nic acid (AA) [29,30], these mediators were also tested for 
PKC~t activation and found to be negative (Table 2). Like- 
wise, phosphatidic acid (PA), reported to stimulate PKC and 
PKC~ kinase activity [31], did not stimulate PKC~t substrate 
phosphorylation. Parallel investigations of autophosphoryla- 
tion activity revealed a response pattern similar to substrate 
phosphorylation (data not shown). 
Table 2 
Activation of PKCtx kinase activity by various phospholipids 
Substrate Relative PKC~t activity 
(cprrdassay) + S.D. 
No cofactors added 2242 + 297 
PS 4888 + 528 
PS/Ptdlns-4,5-P2 9587 _+ 1072 
PS/PDBu 12665 _+ 1169 
PS/DAG 21056 _+ 976 
PS/Ceramide 5687 + 445 
PS/Arachidonic acid 6053 + 178 
PS/Lyso-phosphatidylcholine 3443 + 581 
PS/Phosphatidic acid 4973 + 1771 
Baculovirus produced PKC~t was used for kinase assays using syn- 
tide 2 as a substrate. Kinase assays were carried out in the presence 
of 100% phosphatidylserine (PS) containing micelles. Kinase assays 
in the presence of Ptdlns-4,5-P2 were carried out with mixed mi- 
celles containing 80% PS and 20% Ptdlns-4,5-P2. PDBu was added 
to a final concentration of 100nM, diacylglycerol, (DAG), ceramide, 
arachidonic acid, lyso-phosphatidylcholine and phosphatidic acid 
were added to a final concentration of 1 ~tM. 
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4. Discussion 
Purified PKQt  was found to possess phosphatidylserine 
dependent, high affinity phorbol ester binding capacity, with 
a Kd of 7 nM, which is in the same order of magnitude as 
reported for immunopurified PKD (Kd = 2.2 nM) [9]. These 
data are consistent with an important role of a proline residue 
in the cysteine domains of phorbol ester binding PKCs which 
is conserved in PKQt  (Pro-157 for Cys I and Pro-281 for Cys 
II) [32]. The finding of a high efficient phorbol ester binding of 
the purified enzyme differs from our earlier observations, 
where only weak increase in phorbol ester binding capacity 
of cellular extracts from PKC~t-transfectants was noted [6]. 
Based on the data presented here with purified enzyme, the 
previous failure to detect PDBu binding could be due to rel- 
ative low concentration of PKC~t in mamalian cell extracts or 
a highly efficient blockade of the PKC~t phorbol ester binding 
sites by unknown cellular factors, present in the cellular ex- 
tracts of mamalian transfectants and absent or outnumbered 
in highly PKC~t overexpressing insect cells. 
Diacylglycerol, a main product of the phosphoinositide me- 
tabolism and regarded as the physiological ctivator of most 
PKC isozymes, was found here to be the most potent activa- 
tor of PKQt  in in vitro kinase assays. Of interest is the ob- 
servation that Ptdlns-4,5-P2/phosphatidylserine also served as 
an activator of PKC~t (Table 2), whereas other PKC subtypes 
have been reported to be only weakly activated by Ptdlns-4,5- 
P2. [24,25]. As Ptdlns-4,5-P2 has recently been shown to bind 
to the pleckstrin homology domains of several signal transdu- 
cers [33], it might serve as an additional membrane anchor, 
attaching PKCp, via its pleckstrin homology domain [7] to a 
membrane. 
Phosphorylation assays revealed the synthetic peptides GS 
(PLSRTLSVAALL) and syntide 2 (PLARTLSVAGLPGKK) 
as best in vitro substrates, whereas Kemptide (LRRASLG) 
and an EGF receptor derived peptide (LRTLRR) were only 
weakly phosphorylated. From the natural substrates tested for 
in vitro phosphorylation, only MARCKS (S, Dieterich, un- 
published) and a MARCKS derived peptide (Table 1) could 
be specifically phosphorylated by PKC~t. MARCKS is a 
widely distributed specific PKC substrate, implicated in sev- 
eral cellular functions like secretion, membrane trafficking and 
regulation of the cell cycle [23,34,35]. MARCKS-phosphory- 
lation prevents its binding to calmodulin in the presence of 
calcium and disrupts actin crosslinking activity (for review see 
[23]). Within the MARCKS peptide only one out of five po- 
tential PKC phosphorylation sites, serine 156, was specifically 
phosphorylated by PKC~t (Fig. 3). This finding differs signifi- 
cantly from the MARCKS peptide phosphorylation pattern 
obtained with other PKC subtypes where serines 152, 156 and 
163 were phosphorylated [16]. Serine 160 and serine 167 were 
neither phosphorylated by PKC~t (Fig. 3) nor by other PKC 
subtypes [16]. Phosphorylation of serine 156 versus serines 
152/163 in diverse MARCKS functions has not yet been in- 
vestigated and it remains open, to which extend PKQt  is 
involved in the regulation of MARCKS function and cyto- 
skeletal reorganisation i  vivo. 
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